Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Invested Capital (2016 - 2026)

Insight Molecular Diagnostics' Invested Capital history spans 7 years, with the latest figure at -$31.0 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 157.65% to -$31.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$31.0 million, a 157.65% decrease, with the full-year FY2025 number at -$31.0 million, down 157.65% from a year prior.
  • Invested Capital hit -$31.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$8.1 million in the prior quarter.
  • Over the last five years, Invested Capital for IMDX hit a ceiling of $109.2 million in Q1 2021 and a floor of -$31.0 million in Q4 2025.
  • Historically, Invested Capital has averaged $39.1 million across 5 years, with a median of $35.3 million in 2022.
  • Biggest five-year swings in Invested Capital: skyrocketed 186.47% in 2021 and later plummeted 176.0% in 2025.
  • Tracing IMDX's Invested Capital over 5 years: stood at $66.6 million in 2021, then crashed by 48.35% to $34.4 million in 2022, then tumbled by 33.78% to $22.8 million in 2023, then plummeted by 152.88% to -$12.0 million in 2024, then tumbled by 157.65% to -$31.0 million in 2025.
  • Business Quant data shows Invested Capital for IMDX at -$31.0 million in Q4 2025, -$8.1 million in Q3 2025, and $1.8 million in Q2 2025.